BioInformant

Your Global Leader in Stem Cell Market Research

Home » Stem Cell News » Press Releases » Page 79

Applied StemCell Licenses Its TARGATT™ CHO Cell Technology for Biotherapeutics Development

By Leave a Comment

Applied StemCell Licenses Its TARGATT™ CHO Cell Technology to Twist Bioscience Corp. for Biotherapeutics Development

Milpitas, California, January 19th, 2021 — The multi-platform gene-editing company, Applied StemCell (ASC), announced a commercial license of its TARGATT™ CHO technology to Twist Bioscience (Twist), a global innovative synthetic biology company. Execution of the license agreement was based on the evaluation result of the TARGATT™ CHO cell platform by Twist to assess its suitability for Twist’s antibody discovery, library screening, and bioproduction process. [Read more…]

Results from phase 3 gene therapy trial for painful diabetic peripheral neuropathy has been published online by Clinical and Translational Science

By Leave a Comment

Results from the phase 3 gene therapy trial for painful diabetic peripheral neuropathy (DPN) have been published online by Clinical and Translational Science and suggest excellent safety profile and promising efficacy.
  • VM202 (donaperminogene seltoplasmid) is a first-in-class, proprietary, non-viral, potentially regenerative plasmid DNA gene therapy.
[Read more…]

Jellagen launches JellaGel™, the first Collagen Type 0 Hydrogel taking on the market leading Extracellular Matrix

By Leave a Comment

  • JellaGel™ uses Collagen Type 0 (marine sourced jellyfish) and is non-mammalian.

  • The hydrogel kit is easy to use (with Buffer and Crosslinker).

  • JellaGel™ can be used at room temperature.

Jellagen® Limited, a biotechnology company manufacturing high value Collagen Type 0 derived from jellyfish, announce the launch of their JellaGel™ Hydrogel. 3-dimensaional Hydrogels allow cells to grow and interact with all of their surroundings which makes a huge difference. [Read more…]

Celularity and GX Acquisition Corp. Announce Merger Agreement to Create a Publicly Listed Leader in Allogeneic Cellular Therapy

By Leave a Comment

FLORHAM PARK, N.J. and NEW YORK, Jan. 8, 2021 — Celularity, Inc. (“Celularity”), a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic therapies derived from the postpartum human placenta, and GX Acquisition Corp. (Nasdaq: GXGX), a special purpose acquisition company, today announced they have entered into a definitive merger agreement pursuant to which GX Acquisition Corp. will combine with Celularity. Upon the closing of the transaction, which is expected to occur in the second quarter of 2021, GX Acquisition Corp. will be renamed Celularity Inc., and its common stock and warrants are expected to remain listed on Nasdaq under the new ticker symbols “CELU” and “CELUW.” [Read more…]

Helixmith Announces the Development of Botanical Therapeutic Product for Respiratory Diseases, TADIOS

By Leave a Comment

  • Encouraging animal model efficacy data has been published in Journal of Ethnopharmacology
  • Clinical trial of 100 patients diagnosed with COVID-19 to begin soon in India
  • TADIOS found to have anti-inflammatory, anti-oxidative activities and therapeutic effects in acute lung injury animal model

January 14, 2021 – Helixmith Co., Ltd. has announced that TADIOS (HX110), a respiratory treatment developed by the company, showed lung damage-suppressing capability in an acute lung injury mouse model. The results have been published in the Journal of Ethnopharmacology. Helixmith plans to conduct a clinical trial in India to assess if TADIOS can be used as a COVID-19 treatment. Helixmith has signed an agreement with a contract research organization (CRO) that has extensive experience and capacities in the conduct of clinical trials in India. The clinical trial will be conducted in accordance with the regulations of the Ministry of AYUSH, India’s traditional medicine regulatory body, and will begin in February with 100 subjects. [Read more…]

Shopping cart0
There are no products in the cart!
Continue shopping
0